Business
BioVie Announces Data from Phase 2 Parkinson’s Disease Trial Accepted for Presentation at AD/PD 2023
CARSON CITY, Nev., March 21, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative
About this update from Biovie Inc.
[{"type":"text","content":"CARSON CITY, Nev., March 21, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced data from its Phase 2 Parkinson’s Disease (PD) trial will be presented at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2023), to be held March 28 – April 1, 2023 in Gothenburg, Sweden. Data from the Company’s Phase 2 Trial evaluating NE3107 in Parkinson’s Disease will be presented orally during the symposium Advances in PD and LDB Diagnosis and Drug Development (ID#124). A poster presentation on the pharmacokinetic profile of NE3107 will also be given. Both the oral presentation and poster will be available virtually throughout the event. Details for the presentations are as follows: Oral PresentationTitle - Safety, Tolerability, and Efficacy of NE3107 From A Phase 2, Double-Blind, Placebo-Controlled Study In Levodopa/Carbidopa-Treated Patients with Parkinson's DiseaseDate/Time - Saturday, April 1, 4:00pm Local Time (Hall F1+F2+F3) Presenter - Christopher Reading, PhD Poster PresentationTitle - Effect of NE3107 on the Pharmacokinetics Profile of Carbidopa/Levodopa in Patients with Parkinson’s Disease: A Phase 2, Double-Blind, Placebo-Controlled StudyAuthors: Clarence Ahlem; Christopher Reading, PhD; Joseph Djan; Joseph Palumbo, MD About BioVie BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate NE3107 inhibits inflammatory activation of ERK and NFkB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of Alzheimer’s and Parkinson’s diseases. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease (NCT04669028). Results of a Phase 2 investigator initiated trial (NCT05227820) showing NE3107-treated patients exper...